How Prescription Drug Rebates Work … But Don’t “Work” for YOU

By Vik Mangalmurti and Randy Main, Tonic Advisors

Have you ever gone to a restaurant with a friend and split the bill?  You go, order a meal, talk, and when the check comes your friend says “let me put it on my card, and you can just give me half in cash.  It will save me a trip to the ATM anyway.”  It’s a normal enough interaction and if the total bill plus tip was $40, you fork over a $20 for your share.  In some respects, this is the way standard copay and co-insurance models are intended to work at a doctor’s office or for a hospital stay.  The bill comes, it’s for $1,000, your coinsurance is 20%, so you pay $200 and the insurance (your friend) covers the rest.  This is how health insurance works…most of the time.  It’s just that this isn’t the way it works in the pharmaceutical industry.

Most people probably think that the pharmaceutical industry should work something like the diagram below.

How We May Think the Rx Industry Works

This is the way we buy most goods and services.  Someone makes them in bulk, sells them to a distributor and then the distributor sells them to retailers and the retailer sells them to us.  We assume that the insurance that pays for our prescriptions works similarly.  Most of us think that the difference is that we split the cost with the insurance company when we buy, or that we split the insurance company’s discounted rate. Actually, it often doesn’t work this way.

Instead, you go to the restaurant with your friend, order lunch, and your friend pulls out his credit card.  You pay him $20 for your half.  Your friend pays the $40 tab.  What you don’t know is that your friend’s credit card has a deal with the restaurant.  The restaurant sends 25% of the total tab back as a credit to your friend’s credit card.  In the end, you pay $20 bucks for lunch and your friend paid $10.  That’s a lot closer to the way it actually works in the pharmaceutical industry.

How the Rx Industry Really Works


In the middle of these transactions sits a Pharmacy Benefits Manager (PBM).  The PBM helps insurance companies choose formularies (the lists of drugs the insurer will pay for) based on multiple factors.  Some of these factors are clinical (Drug A is better than Drug B at treating a disease).  Some of these factors are based on very standard cost concerns (Drug A and B are equally effective, but one costs less than the other).  And some are based on undisclosed discounts and rebates, e.g., if the PBM gets to a volume of X on Drug A, the PBM will get 25% of the costs back as a rebate, which can be shared with the insurer.

The Problem


Above board discounts and rebates would not cause problems.  Let’s say your friend had a coupon for $10 off when you bought two entrees.  The price of the lunch would go from $40 to $30, and you would each pay $15.  With the undisclosed rebate, however, you don’t get the benefit of the discount or rebate.  All of the benefit goes to your friend (Your friend pays $10, you pay $20).

In most cases when you have insurance, you have an agreement to cover part of the costs, e.g., copay or coinsurance. The insurer covers the rest. Because you really don’t know what the net cost is to the insurer, you may be actually covering more than the amount you agreed on.  When there is a copay and the cost of the drug is low, you may be paying more than the actual cost of the drug to the insurer in the first place.

In an extreme example, you could pay a $10 copay on a drug that “costs” $15 but where the insurer gets a rebate of $7 (making the actual net cost only $8).  You are out $10, the pharmacist gets that $10 you paid plus an extra $5 from the insurer (total $15), but the insurer gets back $7 thus profiting $2.


The Trump administration seeks to limit use of such rebate agreements.  The impetus is that current agreements often do not result in sound prescribing practices or fair market tactics and competition.  Such agreements can induce insurers to put more costly drugs on formulary.  After rebates and copays, the cost of some brand name drugs –to the insurer— can be lower than generic alternatives.  The patient on the other hand may end up paying more.

The equivalent is your friend recommending going to the restaurant where his credit card gives him or her the rebate, even if the food is worse and more expensive.  After the rebate, it is almost free for your friend.  You, however, are stuck with a big tab, bad food, and an even worse taste in your mouth.

There are likely to be many on the left (or in the party that begins with D) who don’t care for this change in policy because it comes from an administration that begins with “T”.  We do not suggest that the changes proposed are perfect. More specific implementation plans would be helpful for analysis.  We only urge critical analysis of the proposal on the merits of the proposal itself and its goals rather than its political source.  The proposal is a solid start towards increasing transparency in drug pricing.

Please give us feedback

We know we have oversimplified.  There are nuances and complexities we did not delve into; but we did so because we didn’t want to lose sight of our main purpose.  We believe we captured the gist of the dynamics of product (medicine), money, and information flow in the pharmaceutical industry.  As specifics become clear about the proposals, we will update.  As points are made in response to this article, we will respond so that we can keep the discussion going.  We look forward to a virtual dialog with the readership.